EUVIMEDEUVIMED entdecken
Crossref

Prenatal Testing for Cystic Fibrosis in the Central Denmark Region (2012–2023)

Line Dahl Jeppesen, Stine Skibsted Rinder, Naja Becher, Lotte Andreasen, Puk Sandager, Ida Vogel

Fetal Diagnosis and Therapy · 2025

DOI: 10.1159/000546547 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fetal Diagnosis and Therapy, 2025. Verfasst von Line Dahl Jeppesen und 5 weiteren Autor:innen. Beteiligte Einrichtung: ARCEDI Biotech Aps, Vejle, Denmark. Hauptthemen laut MEDLINE: Cystic Fibrosis, Prenatal Diagnosis. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cystic fibrosis (CF) is a severe genetic disorder with a carrier frequency of 1 in 30. In Denmark, prenatal testing is offered when there is a family history of CF or ultrasound anomalies suggest an increased risk of the disease. This study evaluates indications for prenatal CF testing and their outcomes.

Methods

Clinical indications and genetic results were analyzed for pregnancies undergoing CF testing in the Central Denmark Region between August 2012 and 2023. The data were categorized according to clinical indication.

Results

Among 302 prenatal CF tests, echogenic bowel (EB) was the most frequent (44.7%, N = 135), leading to identification of one CF-affected fetus (0.7%). The second most common indication was EB together with non-CF-associated ultrasound findings (29.5%, N = 89), with no CF-affected fetuses. Known CF predisposition due to family history (15.6%, N = 47) identified five affected fetuses (10.6%) and 25 carriers (53.2%). No CF cases were detected in other included groups (N = 31).

Conclusion

These data show that EB has a low positive predictive value for cystic fibrosis in the fetus (1:230) in a country with combined first-trimester screening but no systematic preconception or prenatal screening program for cystic fibrosis. Although the relative risk is increased compared to the general population (1:2,500), EB appears to be a marker of limited clinical utility. In settings without dedicated CF screening strategies, this underscores the importance of considering the most effective allocation of diagnostic resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisPrenatal DiagnosisHumansFemaleDenmarkPregnancyAdultUltrasonography, PrenatalEchogenic BowelGenetic Testing

Stichwörter der Autor:innen

Cystic fibrosisFetal echogenic bowelPrenatal genetic testingPrenatal screeningUltrasound markers

Autor:innen und Institutionen

  • ARCEDI Biotech Aps, Vejle, Denmark.
  • Center for Fetal Diagnostics, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
  • Department for Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark.

Zitieren

APA

Jeppesen, L. D., Rinder, S. S., Becher, N., Andreasen, L., Sandager, P., & Vogel, I. (2025). Prenatal Testing for Cystic Fibrosis in the Central Denmark Region (2012–2023). Fetal Diagnosis and Therapy. https://doi.org/10.1159/000546547

Vancouver

Jeppesen LD, Rinder SS, Becher N, Andreasen L, Sandager P, Vogel I. Prenatal Testing for Cystic Fibrosis in the Central Denmark Region (2012–2023). Fetal Diagnosis and Therapy. 2025. doi:10.1159/000546547

BibTeX
@article{Jeppesen2025,
  author = {Jeppesen, Line Dahl and Rinder, Stine Skibsted and Becher, Naja and Andreasen, Lotte and Sandager, Puk and Vogel, Ida},
  title = {Prenatal Testing for Cystic Fibrosis in the Central Denmark Region (2012–2023)},
  journal = {Fetal Diagnosis and Therapy},
  year = {2025},
  doi = {10.1159/000546547}
}
Kostenlos starten →